JP2009524595A5 - - Google Patents

Download PDF

Info

Publication number
JP2009524595A5
JP2009524595A5 JP2008547721A JP2008547721A JP2009524595A5 JP 2009524595 A5 JP2009524595 A5 JP 2009524595A5 JP 2008547721 A JP2008547721 A JP 2008547721A JP 2008547721 A JP2008547721 A JP 2008547721A JP 2009524595 A5 JP2009524595 A5 JP 2009524595A5
Authority
JP
Japan
Prior art keywords
amount
formulation
surfactant
buffer
lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008547721A
Other languages
English (en)
Japanese (ja)
Other versions
JP5247467B2 (ja
JP2009524595A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/062297 external-priority patent/WO2007076354A2/en
Publication of JP2009524595A publication Critical patent/JP2009524595A/ja
Publication of JP2009524595A5 publication Critical patent/JP2009524595A5/ja
Application granted granted Critical
Publication of JP5247467B2 publication Critical patent/JP5247467B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008547721A 2005-12-20 2006-12-19 安定なタンパク質製剤 Active JP5247467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75215005P 2005-12-20 2005-12-20
US60/752,150 2005-12-20
PCT/US2006/062297 WO2007076354A2 (en) 2005-12-20 2006-12-19 Stable protein formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011141983A Division JP5538309B2 (ja) 2005-12-20 2011-06-27 安定なタンパク質製剤

Publications (3)

Publication Number Publication Date
JP2009524595A JP2009524595A (ja) 2009-07-02
JP2009524595A5 true JP2009524595A5 (enExample) 2010-02-12
JP5247467B2 JP5247467B2 (ja) 2013-07-24

Family

ID=38057529

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008547721A Active JP5247467B2 (ja) 2005-12-20 2006-12-19 安定なタンパク質製剤
JP2011141983A Active JP5538309B2 (ja) 2005-12-20 2011-06-27 安定なタンパク質製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011141983A Active JP5538309B2 (ja) 2005-12-20 2011-06-27 安定なタンパク質製剤

Country Status (24)

Country Link
US (1) US8476239B2 (enExample)
EP (1) EP1962886B2 (enExample)
JP (2) JP5247467B2 (enExample)
KR (1) KR101378194B1 (enExample)
CN (3) CN101584858A (enExample)
AR (2) AR058567A1 (enExample)
AU (1) AU2006330593B2 (enExample)
BR (1) BRPI0622256A2 (enExample)
CA (1) CA2634547C (enExample)
CL (1) CL2010000816A1 (enExample)
DK (1) DK1962886T4 (enExample)
EA (1) EA014232B1 (enExample)
ES (1) ES2436616T5 (enExample)
HR (1) HRP20131196T4 (enExample)
IL (1) IL192104A (enExample)
NO (1) NO347247B1 (enExample)
NZ (1) NZ569108A (enExample)
PE (1) PE20071063A1 (enExample)
PL (1) PL1962886T6 (enExample)
PT (1) PT1962886E (enExample)
RS (1) RS53127B2 (enExample)
SG (1) SG153832A1 (enExample)
TW (3) TW200738261A (enExample)
WO (1) WO2007076354A2 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5096369B2 (ja) 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
CN101584858A (zh) * 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
ES2821436T3 (es) 2008-10-06 2021-04-26 3 D Matrix Ltd Tapón de tejidos
EP2445616B1 (en) * 2009-06-23 2018-05-02 GE Healthcare Bio-Sciences AB Simulator device
GB201009676D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
JP5847418B2 (ja) 2011-03-30 2016-01-20 富士フイルム株式会社 細胞接着性タンパク質
WO2012142434A2 (en) * 2011-04-15 2012-10-18 THE UNITED STATES OF AMERICA, as represented by the secretary, Depart.of Healtth and Human Services Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
EP2709653B1 (en) 2011-04-20 2017-11-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
MX360706B (es) 2011-10-07 2018-11-14 Takeda Pharmaceuticals Co Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas.
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US9302002B2 (en) 2011-10-18 2016-04-05 Coherus Biosciences, Inc. Etanercept formulations stabilized with combinations of sugars and polyols
LT2867251T (lt) 2012-06-29 2019-11-25 Bristol Myers Squibb Co Glikoproteinų agregacijos sumažinimo būdai
EP3466964A1 (en) 2012-07-06 2019-04-10 3-D Matrix Ltd. Fill-finish process for peptide solutions
CA2878508A1 (en) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
US10166299B2 (en) 2012-08-31 2019-01-01 The United States Of America As Represented By The Secretary Dept. Of Health And Human Services National Institutes Of Health AAV mediated aquaporin gene transfer to treat Sjogren's syndrome
PE20191815A1 (es) 2012-09-07 2019-12-27 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
PL2895188T3 (pl) 2012-09-11 2018-06-29 Coherus Biosciences, Inc. Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności
WO2014149067A1 (en) * 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
EP2996772B1 (en) 2013-05-13 2018-12-19 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
CN103385852B (zh) * 2013-08-06 2015-03-11 南京正大天晴制药有限公司 一种盐酸法舒地尔注射液及其制备方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
CN117138022A (zh) 2014-03-10 2023-12-01 三维矩阵有限责任公司 自组装肽组合物
CN106456811B (zh) 2014-03-10 2021-04-02 三维矩阵有限责任公司 肽组合物的灭菌和过滤
CN106132429A (zh) 2014-03-19 2016-11-16 百时美施贵宝公司 使用针对cd40l的域抗体治疗移植物排斥的方法
RU2689145C2 (ru) * 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
EP3134109A1 (en) 2014-04-25 2017-03-01 Bristol-Myers Squibb Company Use of ctla4 compound for achieving drug-free remission in subjects with early ra
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) * 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6675333B2 (ja) 2014-06-23 2020-04-01 ノバルティス アーゲー 部位特異的タンパク質修飾
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
MX391067B (es) 2014-10-01 2025-03-21 Eagle Biologics Inc Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
JP6781508B2 (ja) 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
PE20171328A1 (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
DK3347031T3 (da) * 2015-09-11 2021-04-26 Nutrition & Biosciences Usa 1 Llc Sammensætning, der omfatter et protein og en polyalkoxyfedtforbindelse
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
ES2823279T3 (es) * 2015-12-07 2021-05-06 Merck Patent Gmbh Formulación farmacéutica acuosa que comprende el anticuerpo anti-PD-1 Avelumab
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子15(gdf−15)を使用して代謝障害を処置するまたは軽快させる方法
US10814038B2 (en) 2016-01-06 2020-10-27 3-D Matrix, Ltd. Combination compositions
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
IL266918B2 (en) 2016-12-07 2024-03-01 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
US11384152B2 (en) 2017-05-24 2022-07-12 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
CN119386162A (zh) 2017-12-22 2025-02-07 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
CN108014338A (zh) * 2018-01-22 2018-05-11 安徽未名生物医药有限公司 一种注射用巴利昔单抗冻干粉针及其制备方法
WO2019224842A1 (en) * 2018-05-25 2019-11-28 Dr. Reddy's Laboratories Ltd. Stable fusion protein formulation
US20210179690A1 (en) * 2018-05-25 2021-06-17 Dr. Reddy?s Laboratories Limited Ctla4-ig fusion protein formulation
WO2020003139A2 (en) * 2018-06-26 2020-01-02 Lupin Limited Stable lyophilized dosage form of protein
CN113528510A (zh) * 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
US20220025344A1 (en) 2018-11-26 2022-01-27 Novartis Ag Lpl-gpihbp1 fusion polypeptides
SG11202107606VA (en) 2019-01-15 2021-08-30 Inst Nat Sante Rech Med Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
EP3914282A1 (en) 2019-01-25 2021-12-01 Ospedale San Raffaele S.r.l. Inhibitor of dux4 and uses thereof
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
JP2023507795A (ja) * 2019-12-20 2023-02-27 アントス セラピューティクス, インコーポレイテッド 第XI/XIa因子抗体の医薬製剤および投薬レジメン
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
WO2022162704A1 (en) * 2021-02-01 2022-08-04 Dr. Reddy's Laboratories Limited Compositions comprising fusion protein and analytical attributes thereof
MX2023011262A (es) 2021-03-23 2024-01-12 King S College London Composiciones que comprenden polipeptidos de fusion nkg2d, cxcr2 y dap10/dap12 y metodos de uso de los mismos.
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂
GB202214120D0 (en) 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
IL319340A (en) * 2022-09-29 2025-05-01 Pfizer Immunogenic preparations containing RSV F protein truncation
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
WO2025196207A1 (en) 2024-03-20 2025-09-25 King's College London Compositions and methods for use in depleting senescent cells and treating aging

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589167A (en) * 1993-02-23 1996-12-31 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
SI1516628T1 (sl) 1995-07-27 2013-10-30 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO2003005465A1 (en) 2001-04-25 2003-01-16 Quallion, Llc Rechargeable lithium battery for tolerating discharge to zero volts
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
ATE401909T1 (de) * 2000-07-03 2008-08-15 Bristol Myers Squibb Co Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HUP0303930A3 (en) 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
IL161812A0 (en) 2001-11-13 2005-11-20 Genentech Inc Apo2 ligand/trail formulations
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
DE10204792A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
JP4541157B2 (ja) 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
ES2354610T5 (es) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
JP2007501243A (ja) * 2003-08-04 2007-01-25 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ctla4分子を用いる心臓血管疾患の治療方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1916997B1 (en) * 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
CN101584858A (zh) * 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂

Similar Documents

Publication Publication Date Title
JP2009524595A5 (enExample)
TWI459961B (zh) 長效人類生長激素共軛物之液態配方
CN102712677B (zh) 脂肽组合物和相关方法
ES2313881T3 (es) Formulaciones de vacunas frente al papilomavirus humano.
ES2700925T3 (es) Formulaciones líquidas para conjugado de eritropoyetina de acción prolongada
CN106061468B (zh) 包含TNFR和Fc区的融合蛋白的液体制剂
JP2012515221A5 (enExample)
JP7229999B2 (ja) ダプトマイシン製剤
JP2024099628A5 (enExample)
JP2008535819A5 (enExample)
JP2013500947A5 (enExample)
JP2011506442A5 (enExample)
HRP20161653T1 (hr) Liofilizirane formulacije terapeutskih peptitijela
JP2009540001A5 (enExample)
FI3725330T3 (fi) Polypeptidien stabiilit valmisteet ja niiden käyttötarkoitukset
TWI428140B (zh) A freeze-dried preparation containing influenza vaccine and a method for producing the same
JP2012121894A (ja) Il−1アンタゴニスト製剤
JP2019509311A5 (enExample)
RU2007119724A (ru) Композиции, содержащие эктинэсайдин и дисахарид
ES2431054T3 (es) Formulaciones de los conjugados de PEG-interferón alfa
JP2019512012A5 (enExample)
WO2015190378A1 (ja) 安定なアダリムマブ水性製剤
TWI243057B (en) Formulations for protection of peg-interferon alpha conjugates
ES2365832T3 (es) Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector.
TWI615158B (zh) 多肽之調配物